SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

ELUT

Elutia Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 11h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor NXT-41 FDA clearance decision in Q4 2026 and NXT-41x FDA submission; the $26M non-dilutive capital provides runway through early commercialization, but the widening operating loss and reliance on pipeline catalysts keep the risk profile elevated.

DirectionNeutral
Confidencehigh
Horizonmonths

NXT-41

▲ Bullish Named in this press release
Impact
Phase
Filed/510(k) submission
Time to market
NXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.
Next catalyst
None dated

What to watchWatch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.

Price Chart

Loading chart...

Executive Summary

Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but net loss from continuing operations widened to $6.5M from $1.0M a year ago, driven by higher R&D spending on NXT-41x. The company secured $26M in non-dilutive capital and plans to submit NXT-41x to the FDA in Q4 2026, with cash runway through the first full year of commercialization.

Key Financial Metrics

EPS
−$0.15
est −$0.15 · 0.0%
Revenue
$1.1M
est $1.0M · +13.7% · +20.4% YoY
Rating
in line
Gross Margin
61.7%

Key Facts

  • Q3 2026 net sales $1.1M, up 20.4% YoY from $0.9M
  • Net loss from continuing operations $6.5M vs $1.0M in Q3 2025
  • R&D expense rose $1.9M to $3.0M, supporting NXT-41 and NXT-41x programs
  • Adjusted gross margin (non-GAAP) improved to 85.5% from 81.3%
  • Cash and equivalents $29.1M at Sep 30, 2026; plus $8M Boston Scientific holdback received Oct 1
  • Company secured $26M in non-dilutive capital (Avenue loan, SimpliDerm sale, Boston Scientific escrow release)
  • NXT-41x GLP rabbit study met performance endpoints; FDA submission planned in Q4 2026
  • NXT-41 FDA clearance decision expected in Q4 2026
  • Cardiovascular business strategic process on track for 2026

Financial Impact

Net loss from continuing operations $6.5M, net sales $1.1M, cash $29.1M plus $8M holdback

revenuenet losscashR&D expense

Risk Factors

  • Net loss from continuing operations widened significantly to $6.5M from $1.0M YoY
  • Company is pre-revenue on its lead pipeline (NXT-41x) and dependent on FDA clearances
  • Cash burn rate may accelerate with R&D spending ahead of commercialization

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397149

Track record

7 reports on ELUT

Performance horizon
Filters
  1. Nov 5, 202611d ago Press Release Neutral 4/10 Viewing No price data
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
  3. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
  4. Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
  5. Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
  6. May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
  7. Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026